Early hematologic dynamics and their association with patient-reported symptom burden in breast cancer pharmacotherapy: a prospective cohort study | Synapse
April 12, 2026
Early hematologic dynamics and their association with patient-reported symptom burden in breast cancer pharmacotherapy: a prospective cohort study
Puntos clave
To investigate how early hematologic and inflammatory changes relate to symptom burden in breast cancer patients undergoing pharmacotherapy.
Conducted a prospective cohort study among breast cancer patients receiving pharmacotherapy.
Monitored hematologic and inflammatory changes early in treatment.
Collected patient-reported symptoms at various time points.
Identified significant associations between hematologic dynamics and the severity of patient-reported symptoms.
Inflammatory changes corresponded with increased symptom burden during treatment.
Resumen
Early breast cancer pharmacotherapy induces dynamic hematologic and inflammatory changes associated with patient-reported symptoms, supporting integrated monitoring to improve toxicity management.